Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.
作者信息
Khurana Arushi, Rosenthal Allison C, Mohty Razan, Gaddam Mamatha, Bansal Radhika, Hathcock Matthew A, Nedved Adrienne N, Durani Urshila, Iqbal Madiha, Wang Yucai, Paludo Jonas, Villasboas J C, Dingli David, Kourelis Taxiarchis, Leung Nelson, Alkhateeb Hassan, Ruff Michael W, Gallo de Moraes Alice, Vergidis Paschalis, Herrmann Joerg, Kenderian Saad S, Bennani N Nora, Johnston Patrick B, Ansell Stephen M, Lin Yi
机构信息
Division of Hematology Mayo Clinic, Rochester, MN, USA.
Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.
出版信息
Blood Cancer J. 2024 Aug 12;14(1):136. doi: 10.1038/s41408-024-01119-2.
Abstract
摘要
相似文献
1
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.嵌合抗原受体T细胞疗法相关噬血细胞性淋巴组织细胞增生症综合征：临床表现、结局及管理
Blood Cancer J. 2024 Aug 12;14(1):136. doi: 10.1038/s41408-024-01119-2.
2
Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).嵌合抗原受体T细胞免疫疗法相关噬血细胞性淋巴组织细胞增生症：与细胞因子释放综合征相比的发病机制、临床表现、诊断及管理（综述）
Mol Med Rep. 2025 Aug;32(2). doi: 10.3892/mmr.2025.13578. Epub 2025 May 26.
3
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.使用抗细胞因子疗法治疗嵌合抗原受体T细胞（CAR-T）疗法相关噬血细胞性淋巴组织细胞增生症（HLH）：1例说明性病例及文献综述
Leuk Lymphoma. 2021 Jul;62(7):1765-1769. doi: 10.1080/10428194.2021.1881507. Epub 2021 Feb 9.
4
[The diagnosis and treatment of chimeric antigen receptor T-cell associated hemophagocytic lymphohistiocytosis].嵌合抗原受体T细胞相关噬血细胞性淋巴组织细胞增生症的诊断与治疗
Zhonghua Nei Ke Za Zhi. 2025 Jan 1;64(1):77-82. doi: 10.3760/cma.j.cn112138-20240506-00284.
5
Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.一名接受嵌合抗原受体T细胞疗法治疗的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤患者发生噬血细胞性淋巴组织细胞增生症。
Immunotherapy. 2024;16(18-19):1105-1111. doi: 10.1080/1750743X.2024.2409622. Epub 2024 Oct 17.
6
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.噬血细胞性淋巴组织细胞增生症在接受CD19嵌合抗原受体T细胞治疗后发病时间不一。
Br J Haematol. 2019 Oct;187(2):e35-e38. doi: 10.1111/bjh.16155. Epub 2019 Aug 13.
7
Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.CD19 特异性嵌合抗原受体 T 细胞治疗后噬血细胞性淋巴组织细胞增生症样毒性（carHLH）。
Br J Haematol. 2021 Aug;194(4):701-707. doi: 10.1111/bjh.17662. Epub 2021 Jul 15.
8
Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.嵌合抗原受体 T 细胞疗法与肾毒性：从诊断到治疗策略。
Int Immunopharmacol. 2020 Dec;89(Pt B):107072. doi: 10.1016/j.intimp.2020.107072. Epub 2020 Oct 12.
9
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).免疫效应细胞相关噬血细胞性淋巴组织细胞增生症样综合征（IEC-HS）
Hematol Oncol Clin North Am. 2025 Jun;39(3):617-643. doi: 10.1016/j.hoc.2025.02.005. Epub 2025 Mar 29.
10
Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy.一名血液系统恶性肿瘤患者在接受实验性嵌合抗原受体（CAR）-T细胞治疗后出现非常罕见的极高铁蛋白水平并伴有细胞因子释放综合征。
Clin Chim Acta. 2024 Jun 1;559:119704. doi: 10.1016/j.cca.2024.119704. Epub 2024 Apr 30.
引用本文的文献
1
Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review.癌症免疫治疗中的静脉血栓栓塞事件：一项叙述性综述。
J Clin Med. 2025 Jul 11;14(14):4926. doi: 10.3390/jcm14144926.
2
[Management of side effects of CAR T cells].[嵌合抗原受体T细胞副作用的管理]
Inn Med (Heidelb). 2025 Jul 8. doi: 10.1007/s00108-025-01944-y.
3
Chimeric antigen receptor T cell immunotherapy‑associated hemophagocytic lymphohistiocytosis: Pathogenesis, clinical manifestation, diagnosis and management compared with cytokine release syndrome (Review).嵌合抗原受体T细胞免疫疗法相关噬血细胞性淋巴组织细胞增生症：与细胞因子释放综合征相比的发病机制、临床表现、诊断及管理（综述）
Mol Med Rep. 2025 Aug;32(2). doi: 10.3892/mmr.2025.13578. Epub 2025 May 26.
4
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.多发性骨髓瘤中的T细胞重定向疗法：细胞因子释放综合征和免疫效应细胞相关神经毒性综合征之外的发病机制及毒性管理
Cancers (Basel). 2025 Apr 30;17(9):1514. doi: 10.3390/cancers17091514.
5
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).免疫效应细胞相关噬血细胞性淋巴组织细胞增生症样综合征（IEC-HS）
Hematol Oncol Clin North Am. 2025 Jun;39(3):617-643. doi: 10.1016/j.hoc.2025.02.005. Epub 2025 Mar 29.
本文引用的文献
1
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.免疫效应细胞相关性噬血细胞性淋巴组织细胞增生症样综合征。
Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9.
2
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).单中心应用阿那白滞素治疗类固醇难治性免疫效应细胞相关性神经毒性综合征（ICANS）的经验。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003847.
3
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.描述接受 CD22 CAR T 细胞治疗的患者中以细胞因子释放综合征（CRS）为表现形式的噬血细胞淋巴组织细胞增生症（HLH）样综合征。
Blood. 2021 Dec 16;138(24):2469-2484. doi: 10.1182/blood.2021011898.
4
Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy.CD19 特异性嵌合抗原受体 T 细胞治疗后噬血细胞性淋巴组织细胞增生症样毒性（carHLH）。
Br J Haematol. 2021 Aug;194(4):701-707. doi: 10.1111/bjh.17662. Epub 2021 Jul 15.
5
Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-A Case Report.体外血液净化在嵌合抗原受体T细胞疗法后治疗严重难治性神经毒性中的新应用——一例报告
Crit Care Explor. 2021 Jun 29;3(7):e0472. doi: 10.1097/CCE.0000000000000472. eCollection 2021 Jul.
6
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?免疫治疗或细胞治疗后细胞因子释放综合征中的持续肾脏替代治疗？
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000742.
7
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).成人造血干细胞移植和嵌合抗原受体T细胞疗法后继发性噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征的诊断与管理；文献综述及代表自身免疫性疾病工作组（ADWP）和移植并发症工作组（TCWP）对欧洲血液和骨髓移植协会（EBMT）中心的实践调查
Front Immunol. 2020 Mar 31;11:524. doi: 10.3389/fimmu.2020.00524. eCollection 2020.
8
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.CD4/CD8 T 细胞选择影响嵌合抗原受体（CAR）T 细胞效力和毒性：一项抗 CD22 CAR T 细胞试验的 I 期更新结果。
J Clin Oncol. 2020 Jun 10;38(17):1938-1950. doi: 10.1200/JCO.19.03279. Epub 2020 Apr 14.
9
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.噬血细胞性淋巴组织细胞增生症在接受CD19嵌合抗原受体T细胞治疗后发病时间不一。
Br J Haematol. 2019 Oct;187(2):e35-e38. doi: 10.1111/bjh.16155. Epub 2019 Aug 13.
10
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.成人噬血细胞性淋巴组织细胞增生症的治疗建议。
Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16.
Zotero 插件